Royalty Pharma publishes UBS Global Biopharma Conference transcript
RPRX•Royalty Pharma expects annual capital deployment to exceed its $2 billion-$2.5 billion target as pharmaceutical R&D co-funding expands. The company also said third-quarter earnings beat expectations and prompted a guidance increase.
1. Deployment and earnings
Royalty Pharma expects annual capital deployment to rise beyond its stated $2 billion-$2.5 billion target as pharmaceutical R&D co-funding expands. Management views Chinese royalty acquisitions as additional to existing deployment goals, targeting streams from drugs licensed to Western pharmaceutical companies. Christopher Hite cited U.S. accounting rules that allow pharmaceutical partners to expand pipeline spending through external funding without reducing earnings per share. Third-quarter earnings beat expectations, prompting a guidance increase; Tremfya, Voranigo and Evrysdi contributed to growth.




